Atomo Diagnostics Ltd (AT1)

___:___ · AUD

0.00

(0.00)

VOLUME

DIV YIELD

PE RATIO

1 YR RETURN

52 WEEK RANGE

1 YR RETURN

AT1 Chart

Advanced

AT1's Principal Activity is the development and sale of medical devices.

Share Price Activity

Last (Price)
Change	0.00 (0.00)
Bid / Ask	-
Volume
Volume (4w avg)
Turnover
Open
Day Range	-
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr)	-16.16%
vs ASX 200 (1yr)	-21.30%

Size

Market Capitalisation
ASX Rank	886 of 2,466
Sector Rank	73 of 177

Key Information

Shares Issued
Sector	Healthcare
Similar Companies	AGH / BPH / ZLD
EPS	$0.00
DPS	$0.00
NTA per share	$0.00

Broker Consensus

AT1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date	Heading	Pages	File Size	Time

Company Overview

Atomo Diagnostics Limited (AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office	Leichhardt NSW 2040
Website	www.atomodiagnostics.com
Registry	Link Market Services
Auditor	BDO Audit Pty Ltd
Date Listed	16 Apr 2020

Upcoming Calendar

No calendar entries available.

Dividend History

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Ms Constance (Connie) Bernadette Carnabuci	Non-Executive Director	Feb 2020	Ms Constance (Connie) Bernadette Carnabuci Non-Executive Director Ms Carnabuci has over 30 years of experience advising intellectual property and technology businesses in Australia and across Asia on commercial, corporate and regulatory matters. Ms Carnabuci holds an executive role as the General Counsel of the Australian Broadcasting Corporation. She is a professional Non-Executive Director and currently serves on the Board and the Remuneration Committee of OFX. Ms Carnabuci is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She serves as the Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.
Dr Curt Harold LaBelle	Non-Executive Director	Oct 2016	Dr Curt Harold LaBelle Non-Executive Director Dr LaBelle has been involved in the healthcare industry for 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF). He also serves as a director on the boards of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Dr LaBelle is also the member of Risk committee.
Mr John Perry Keith	Non-Executive Chairman, Non-Executive Director	Dec 2011	Mr John Perry Keith Non-Executive Chairman, Non-Executive Director Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is also the member of Risk committee.
Mr John Michael Kelly	Founder, Managing Director	Apr 2010	Mr John Michael Kelly Founder, Managing Director Mr Kelly was into developing and commercialising medical devices for more than 20 years to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of Mirage Swift and Activa mask systems.
Dr Paul Alexander Kasian	Non-Executive Director	N/A	Dr Paul Alexander Kasian Non-Executive Director Dr Kasian is an experienced executive director in both domestic and international companies in senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. Previously he served as a Non-Executive Director, then Chairman and CEO of Genetic Technologies Limited (appointed 12 December 2013 and resigned 23 September 2019). Dr Kasian is the Chair of the Risk Committee.

Show All

Director Interests

The current holdings of AT1 directors.

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Curt LaBelle	30/06/2020	N/A	63,851,280	3,600,000	N/A
John Kelly	30/06/2020	7,370,248	66,160,000	2,000,000	N/A
John Keith	30/06/2020	3,261,056	N/A	3,600,000	N/A
Constance (Connie) Carnabuci	30/06/2020	N/A	75,000	N/A	N/A
Paul Kasian	30/06/2020	N/A	100,000	N/A	N/A

Show All

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Sep 25, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name	Shares	Capital
Dalraida Holdings Pty Limited	66,160,000	11.79%
Global Health Investment Fund I Llc	63,851,280	11.38%
Walker Group Holdings Pty Ltd	46,660,718	8.32%
National Nominees Limited	32,478,361	5.79%
J P Morgan Nominees Australia Pty Limited	18,556,834	3.31%
HSBC Custody Nominees (Australia) Limited	17,624,130	3.14%
Blueflag Holdings Pty Ltd	13,760,000	2.45%
Grand Challenges Canada	11,390,824	2.03%
Liverbird Pty Ltd	9,731,653	1.73%
Sokolov Pty Ltd	9,202,181	1.64%
I D E Pty Ltd <Atf Ide Trust>	9,032,248	1.61%
Mark Andrew Smith	7,790,224	1.39%
John Michael Kelly	7,370,248	1.31%
Leo James Lynch & Judith Anne Beswick	7,321,121	1.30%
Bnp Paribas Noms Pty Ltd	6,972,741	1.24%
Hsbc Custody Nominees (Australia) Limited A/C 2	6,528,750	1.16%
Mr Ian Fredrick Johnson	6,079,560	1.08%
Bosana Nominees Pty Ltd	5,881,496	1.05%
Ruth Karen Devney	5,626,408	1.00%
Nicola Jayne Rigby	4,846,220	0.86%

Show All

Shareholder Distribution

Holding Size	1 - 1,000	1,001 - 5,000	5,001 - 10,000	10,001 - 100,000	100,001+	Total
No. of Shareholders	0	0	167	589	328	1,084

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Name	Last Notice	Total Shares	Shares Held (%)
John Kelly	25/09/2020	73,530,248	13.11
Ellerston Capital Limited	25/09/2020	34,375,000	6.13
Perennial Value Management Limited	25/09/2020	41,762,504	7.44
Global Health Investment Fund I LLC	25/09/2020	63,851,280	11.38
Walker Group Holdings Pty Limited	19/10/2020	37,660,718	6.70

Shareholders Buying

Date	Name	Bought	Previous %	New %
11-06-20	Perennial Value Management Limited	5,742,335	6.42	7.44
29-05-20	Perennial Value Management Limited	6,135,382	5.33	6.42
16-04-20	Walker Group Holdings Pty Limited	--	--	10.39
16-04-20	Ellerston Capital Limited	--	--	6.13

Shareholders Selling

Date	Name	Sold	Previous %	New %
19-10-20	Walker Group Holdings Pty Limited	9,000,000	8.32	6.70
25-08-20	Perennial Value Management Limited	6,133,553	7.44	6.35
07-05-20	Walker Group Holdings Pty Limited	11,625,002	10.39	8.32
30-04-20	Perennial Value Management Limited	6,052,713	6.41	5.33

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Historical Data

Year	Closing Price	Last Trade
2020	$0.34	30 June

AT1 Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.

New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!

Atomo Diagnostics Ltd (AT1)